![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 0114-9954
Source: Reactions Weekly, Vol.1, Iss.1326, 2010-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Risedronic acid abrogates anastrozole-induced bone loss
Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Anastrozole use appears to increase the risk of bone mass loss
Reactions Weekly, Vol. 1, Iss. 1081, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dasatinib-related bleeding "mild and manageable"
Reactions Weekly, Vol. 1, Iss. 1259, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
More BMD loss with anastrozole than tamoxifen in ATAC
Reactions Weekly, Vol. 1, Iss. 1108, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Background to and Management of Treatment-Related Bone Loss in Prostate Cancer
By Berruti A.
Drugs & Aging, Vol. 19, Iss. 12, 2002-01 ,pp. :